What is the role of pembrolizumab (Keytruda) in the treatment of non-muscle invasive bladder cancer?

Updated: Feb 23, 2021
  • Author: Kara N Babaian, MD, FACS; Chief Editor: Bradley Fields Schwartz, DO, FACS  more...
  • Print

Another option is pembrolizumab (Keytruda), which is indicated for treatment of BCG-unresponsive, high-risk, non–muscle-invasive bladder cancer with CIS with or without papillary tumors in patients who are ineligible for, or have elected not to undergo, cystectomy. Approval was supported by the KEYNOTE-057 study, which showed a complete response rate of 41% in patients who received pembrolizumab. The median duration of response was 16.2 months. [102, 103]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!